If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmpeak Energy Regulatory News (AMP)

Share Price Information for Ampeak Energy (AMP)

Share Price is delayed by 15 minutes
Get Live Data
2.55    -0.20 (-7.27%)
Bid:
2.50
Ask:
2.60
Spread: 0.10 (4.00%)
Market Cap: £18.48m
AMP Live PriceLast checked at - London Stock Exchange

Intraday Ampeak Energy Share Chart

Partner Update

25 Oct 2010 07:00

RNS Number : 9104U
Amphion Innovations PLC
25 October 2010
 



 

 

EU certification for colour X ray technology will see the end of liquid flight ban

Major milestone for Amphion Partner Company, Kromek

 

London and New York, 25 October 2010 - Amphion Innovations plc (LSE: AMP) ("Amphion" or the "Company"), the developer of medical and technology businesses, today announces that its Partner Company, Kromek, which specialises in the development of disruptive technology solutions for a range of commercial markets including airport and border security, has received official European Union (EU) certification to provide colour x-ray liquid detection systems to all European airports.

 

By April 2011, liquid items bought in transit (i.e. duty free purchases) will be allowed on board, providing the appropriate security measures, such as screening, are in place at the airports concerned. The results of the European Civil Aviation Conference (ECAC) led trials establish that the technology is ready to allow the 2011 deadline to be met by the airports. By April 2013, the ban will be lifted completely, allowing the carriage of liquids on flights across Europe.

 

Kromek's Bottle Scanner has qualified as a Category B device that has achieved Type 1 and Type 2 100% capability and has been officially tested, verified and authorised by ECAC. As of now, all EU airports are free to buy and implement Kromek's Bottle Scanner product, opening the company to the multi million dollar airport security market. 

 

The move marks a breakthrough in airport security. As the threat from liquid threat has become greater, airport security officials are seeking appropriate technology to mitigate this threat. For the first time, airports can purchase tested, approved, and secure technology that will allow authorities to relax the ban on liquid on flights.

 

Dr. Arnab Basu, CEO of Kromek, said, "It's a significant milestone for Kromek as the approved listing is vindication that colour x-ray detection has been proven. The next generation of X-ray technology has arrived, with a market ready machine that can detect liquid threat.

 

"The threat from Liquid, Aerosol and Gel (LAG) based explosives became apparent in August 2006 following discovery of a plot to use such devices aboard multiple transatlantic flights. Although Kromek had not set out to produce such equipment we were quick to realise with our capabilities we had the versatility to produce a solution for this market need.

 

Kromek's verified and approved solution effectively guards against such a possibility. It is a major step forward in the fight against global terrorism where liquid is increasingly becoming a common tool for terrorist use."

 

Kromek's revolutionary technology signals a new era in colour x-ray detection, and a market-changing development in aviation security. The company is introducing to the sector a pioneering form of detection, which has been likened to the advent of colour TV, from black and white, in terms of significance and market potential.

 

Richard Morgan, CEO of Amphion and Chairman of Kromek, said, "This approval by the ECAC is a major milestone for Kromek. Kromek's proven technology meets a previously unmet need in airport security. Kromek's Bottle Scanner should make a major contribution to a more efficient security system within the European markets."

 

Dr. Basu concluded, "The next year and beyond is extremely exciting for us. Kromek will continue to see strong growth over the coming years as our innovative solutions to many previously intractable problems captures the imagination.  Our groundbreaking technology not only provides products to the airline security market but has the opportunity for development into a range of products for many highly lucrative markets such as medical and industrial fields."

 

For further information please contact

Amphion Innovations plcCharlie Morgan +1 (212) 210 6224

Cardew GroupTim Robertson/ James Milton+44 20 7930 0777

Charles Stanley (Nominated Adviser) Mark Taylor+44 20 7149 6000

 

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 10 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web: www.amphionplc.com

About Kromek

Kromek was spun out of Durham University's physics department and specialises in the development of disruptive technology solutions for a broad range of commercial markets. It is currently pioneering digital colour imaging for x-rays and advanced 3D imaging for the medical, security, industrial inspection and defence markets. The company has successfully pioneered a revolutionary 3D x-ray technology, which has huge commercial benefits for a range of sectors, especially the airline security industry, where it is uniquely placed to fulfil an increasing, necessary worldwide demand for liquid explosive detection at airports.

On the web: www.kromek.com

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAFEAFWEFSSEIS
Date   Source Headline
3rd Mar 20167:00 amRNSConvertible Promissory Note Extended
7th Jan 20167:00 amRNSDirectors' Dealings
5th Jan 20167:00 amRNSConvertible Promissory Note Terms Extended
26th Nov 20157:00 amRNSAdditional Draw on Loan Facility
5th Nov 20157:00 amRNSPartner Company m2m Imaging Corp. to merge
30th Oct 20154:20 pmRNSDeath of a Director - Replacement
30th Oct 20153:50 pmRNSDeath of a Director
17th Sep 20157:00 amRNSAmphion to present in London
16th Sep 20157:00 amRNSDirectors' Dealings
10th Sep 20157:00 amRNSDataTern Receives Favourable Ruling
3rd Sep 20157:00 amRNSInterim Results
28th Aug 20159:08 amRNSHolding(s) in Company
7th Aug 20155:15 pmRNSResult of AGM
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied
1st Jul 20155:07 pmRNSHolding(s) in Company
23rd Jun 20158:47 amRNSPartner Company raises £22 million
23rd Jun 20157:00 amRNSPreliminary Results
5th Jun 20157:00 amRNSPlacing to raise £1.54 million
19th May 20152:35 pmRNSAppointment of broker
15th Apr 20157:01 amRNSFDA Results
7th Apr 20157:00 amRNSShares Issued for Exercised Warrants
2nd Apr 20157:01 amRNSFirst Day of Dealings of Amphion Partner Company
24th Mar 20153:28 pmRNSIssue of Shares
20th Mar 20157:01 amRNSMotif Bio Ltd Update Re Intention to Float
26th Feb 20157:00 amRNSIssue of Equity
9th Feb 20157:00 amRNSDirector/PDMR Shareholding
2nd Feb 20154:18 pmRNSReissue: Partner Company's Intention to Float
2nd Feb 20158:00 amRNSPartner Company's Intention to Float on AIM
22nd Jan 20151:15 pmRNSDirector/PDMR Shareholding
19th Jan 20157:00 amRNSLandmark Acquisition & Update by Partner Company
6th Jan 20157:00 amRNSDataTern Receives Favourable Appeal Ruling
24th Sep 20147:00 amRNSDirectors' Dealings
19th Sep 20147:00 amRNSHalf Yearly Report
9th Sep 20147:00 amRNSAdditional Draws on Loan Facility
28th Aug 20147:00 amRNSDirectorate Change
7th Aug 20144:51 pmRNSResult of AGM and EGM
10th Jul 20149:10 amRNSDirectors' Dealings
8th Jul 20147:00 amRNSAmphion Partner Motif Can Help Solve Health Crisis
20th Jun 20147:00 amRNSNotice of EGM
18th Jun 20147:00 amRNSFinal Results
5th Jun 20147:00 amRNSNew Loan Facility
14th Apr 20147:00 amRNSAppeal Ruling
7th Apr 20145:03 pmRNSDirector/PDMR Shareholding
28th Jan 20147:00 amRNSConvertible Promissory Note Extension
12th Dec 20137:00 amRNSUpdate on Covertible Promissory Note
13th Nov 20134:33 pmRNSDirector/PDMR Shareholding
13th Nov 20137:00 amRNSPartner Company Update
16th Oct 20137:02 amRNSPartner Company IPO
24th Sep 20137:00 amRNSHalf Yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.